Alpha Teknova, Inc. (TKNO)

Market Cap	143.61M -48.2%
Revenue (ttm)	40.52M +7.4%
Net Income	-17.26M
EPS	-0.32
Shares Out	53.59M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	161,625
Open	2.780
Previous Close	2.740
Day's Range	2.560 - 2.840
52-Week Range	1.910 - 7.480
Beta	0.33
Analysts	n/a
Price Target	n/a
Earnings Date	May 7, 2026

About TKNO

Alpha Teknova, Inc. produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company’ primary products include pre-poured media plates for cell growth and cloning; liquid microbial culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and dr...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Jun 25, 2021
• Employees: 158
• Stock Exchange: NASDAQ
• Ticker Symbol: TKNO
• Website: https://www.teknova.com

Financial Performance

In 2025, Alpha Teknova's revenue was $40.52 million, an increase of 7.35% compared to the previous year's $37.75 million. Losses were -$17.26 million, -35.47% less than in 2024.